DANIEL J. LEVANGIE - 01 Jul 2023 Form 3 Insider Report for Renalytix plc (RNLX)

Role
Director
Signature
/s/ Katie Kazem, Attorney-in-Fact
Issuer symbol
RNLX
Transactions as of
01 Jul 2023
Transactions value $
$0
Form type
3
Filing time
03 Jul 2023, 16:20:51 UTC
Previous filing
12 Jun 2023
Next filing
22 Nov 2023
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding RNLX Stock Option (right to buy) 01 Jul 2023 Ordinary Shares 40,000 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 One fourth (1/4th) of the shares subject to the option award vested on August 31, 2022, and one sixteenth (1/16th) of the shares subject to the option award vested or shall vest in equal quarterly installments thereafter, subject to the Reporting Person's continuous service.
F2 The exercise price is 4.95 pounds sterling. The U.S. dollar equivalent of the exercise price is $6.25 using the Bank of England rate as of June 29, 2023 (1.00 pound sterling = $1.262).

Remarks:

Exhibit List - Exhibit 24 - Power of Attorney